The present invention relates to microneedles and a method of manufacture. Furthermore the invention relates to a biological fluid monitoring device including said microneedles and in particular but not exclusively to a sensor device that is minimally invasive and which in particular monitors the glucose level of an individual.
The most common glucose measurement available today is the ‘finger stick’ glucose meter. Diabetic patients would normally perform the test between 3 to 10 times a day, which is painful and causing the finger to sore. Due to discomfort, the non-compliance with a finger stick test is partly responsible for the increase in the uncontrolled condition. Furthermore, such tests only provide a discrete observation of glucose level that changes continuously with time, thus it cannot allow the patient to monitor how the glucose level reacts with insulin, exercise, food and other factors. Therefore, a continuous glucose monitoring (CGM) system is critical for the adjustment of correct insulin dosing ratios for food intake and correction of hyperglycemia. An effective CGM system will significantly reduce the risk of health complications associated with diabetes and therefore enhancing the patients' quality of life and their life expectancy.
More recently, individuals can take their own glucose measurement using special instruments, for example in people with diabetes. The special instruments may include microneedles which have the advantage that they may be applied to the body via the skin without pain and bleeding. Microneedles are sufficiently long enough to penetrate through the stratum corneum skin layer and into the epidermal skin layer but also are sufficiently short not to penetrate the dermal layer. Known devices may be used to take individual samples or they may form part of a device that can be used to sample and filter fluids within the skin tissue on a continual basis. An example of a device using microneedles can be found in US 2009/0043250.
Known devices have limitations, in that they are used to measure very small amounts of substances in the body but they may not be sensitive enough to accurately distinguish some analytes from others in the body with the required level to give an accurate measurement for an accurate diagnosis of the condition of the individual. In the case of glucose for example, the glucose level in the body is less than one thousandth that of other chemicals in the body and so there is a need for increased sensitivity of monitoring or measuring devices.
The present invention seeks to overcome the problems associated with the prior art by providing an accurate way of measuring chemicals in the body and in particular the invention provides a continual way of monitoring biological fluid, with minimal impact on the individual that is being monitored. Furthermore, the invention allows for real time evaluation of biological fluids in a minimally-invasive, painless, and convenient manner and with a high degree of sensitivity for materials within the body. In addition the present invention overcomes the problems of having blocked needles and difficulties in fluid extraction that are associated with known devices.
According to a first aspect of the present invention there is provided a microneedle device for a sensor including at least one microneedle having one or more nanowires on a surface of said at least one microneedle. Typically the microneedle does not have a bore.
It is envisaged that the microneedle device has a plurality of said microneedles formed as an array on a support surface, each microneedles having one or more nanowires on the surface thereof. Typically the microneedles are arranged in alignment with one another so there is a regular array of microneedles on the support surface.
Preferably, the at least one microneedle having one or more nanowires on a surface of said microneedles has a membrane disposed there over as to at least partially cover the one or more nanowires.
It is envisaged that the microneedles and/or the nanowires are functionalized for the detection of an analyte.
It is envisaged that the membrane is an ion selective membrane. The ion selective membrane is arranged such that one or more analytes can pass through the membrane. Typically the membrane is a porous polymeric membrane and the pores may be selected for filtering out particles or molecules in the biological fluid that are above a certain size.
Preferably the nanowires are formed of Zinc Oxide.
According to a second aspect of the invention there is provided a device for the monitoring of biological fluid from an individual, said device comprising an array of microneedles, characterized that one or more of said microneedles includes one or more nanowires on a surface of said microneedles, said one or more of said microneedles and/or nanowires having been functionalized with material that can interact with a material in the biological fluid of an individual that contacts said microneedles so said device can monitor one or more anayltes in the biological fluid. The biological fluid typically is interstitial fluid in the skin.
It is envisaged that there is a membrane disposed to lie over said one or more microneedles, said membrane being porous so that fluid can pass through the membrane and come into contact with the nanowires and microneedles.
It is preferred that the microneedles/nanowires are in two or more arrays with each array being functionalized with different material from another array.
Preferably the microneedles having nanowires thereon act as a working electrode for the device which is a sensor for analytes in the biological fluid of an individual.
Preferably the microneedles on which the nanowires have been formed have a membrane disposed thereon so as to at least partially cover the one or more nanowires.
It is envisaged that the biological fluid is interstitial fluid. Typically interstitial fluid is the main component of the extracellular fluid in the body that bathes the cells of the body.
Preferably at least one of the analytes in the biological fluid is glucose.
Typically the sensor has two electrodes, a working and a reference electrode. Alternatively the sensor has three electrodes, a working, counter and reference electrode. The needles are divided into two or three groups according to whether there are two or three electrodes.
It is envisaged that the support structure be coated with an insulating material to isolate areas which are not microneedles from analytes.
It is envisaged that the device is releasably securable to a control system, said control system including controls for the sensor and a transmitter.
Preferably the control system includes an accelerometer attached thereto.
It is envisaged that data from the transmitter or accelerometer is transmitted using wireless communication, preferably the transmission being in real time although data can be stored and transmitted at another point in time.
It is further envisaged that the control system includes a temperature sensor to monitor the body temperature of a wearer of the device. The sensor reading can be adjusted to compensate for the effect of temperature on the sensor output. In addition though according to the temperature detected by the device then drug delivery can be altered accordingly as the temperature can be an indication of the metabolism of the individual and drugs may have to be delivered at a rate to suit an individual's metabolic rate.
According to a further aspect of the invention there is provided a monitoring system provided by a device according to the second embodiment of the invention in combination with a control system including controls for the sensor, a transmitter and an accelerometer.
Preferably the monitoring system includes a receptor on the nanostructures, said monitoring system being arranged to monitor heart diseases, stroke, chronic obstructive pulmonary diseases or asthma.
It is envisaged that the technology is particularly useful to measure diabetes but it can be used for monitoring other chronic diseases, such as heart diseases, stroke, chronic obstructive pulmonary diseases, asthma and cancers etc., through the use of an appropriate receptor at the surface of the nanostructures formed of the microneedles and nanowires.
According to a further aspect of the invention there is provided a method of fabricating nanowires onto microneedles, said method including forming a seed layer onto the microneedles and rotating said microneedles so that a centrifugal force is formed that draws the spray of material along the length of the microneedles to coat the surface of the microneedles following which the nanowires are formed from the seed layer.
Preferably the seed layer is formed on the microneedles by spraying.
It is envisaged that the seed layer is subsequently annealed to initiate nanowire production by growth of said nanowires grown from the surface of a microneedle.
As an alternative the seed layer is formed on the microneedles by plasma vapor deposition (PVD).
Where the seed layer is deposited by plasma vapour deposition (PVD) on the microneedles the sample is rotated at an angle to distribute the seed layer evenly all around the microneedles. In this production process the seed layer does not need to be annealed. It is desirable that the sample is not perpendicular to the incoming material. Samples are usually rotated in PVD for a more even distribution but in the current invention the rotation is at an angle to get the material to deposit on the sides of the features. PVD normally will not deposit onto the side of vertical features and this is why the angled rotation is required.
Preferably the material to form the seed layer is zinc acetate.
An embodiment of the invention will now be described by way of example only with reference to and as illustrated in the accompanying Figures in which:
A prior art biological fluid monitoring device is shown generally as 150 in
The device itself forms a first part of a monitoring system and this first part is attached to a second part that is formed of the controls 104 which can collate and record data.
The microneedles 1 typically provide as an array that can come into contact with the body. The microneedles allow for the uptake of interstitial fluid from under the surface of the skin. The length of the needles will be sub in the region of 500 to 1500 μm, more particularly 700 to 1000 μm, meaning the device will be entirely painless as the microneedles are sized to avoid or minimize contact with nerve endings in the biological tissue, such as the dermis, thereby eliminating or reducing pain when the microneedles are inserted, for example into the skin. The microneedles are attached to a substrate 102 to which the base of the microneedle(s) is secured or integrated, and at least one reservoir/fluid collection chamber 101 and/or sensor 102 is in communication with the array of microneedles. Fluid can flow from the interstitial fluid by way of a bore in the microneedle that allows the fluid to flow into reservoir 101 where the sensors are situated.
An alternative process to producing microneedles using a seed layer is that where the needles are made from a polymer then the microneedles may be made by injection moulding.
The microneedles themselves again can be constructed from a variety of materials including metals, ceramics, polymers, composites. As shown in 2a) the microneedles are fabricated to a length of 700-1000 micrometers as this allows the microneedles to penetrate into the skin and on into the epidermis so that the nanowires that are on the microneedles can be used to monitor, for example glucose that is present in the interstitial fluid. The microneedles can be straight or as shown they may have a tapered shaft but generally where there is no tapering to an apex, the device is referred to as a microtube.
The microneedles are coated with a conductor such as gold or a carbon ink or indeed graphene 3 as shown in
As shown in
In
In
A sensor that forms part of a biological fluid monitoring device is shown generally as 200 in
The nanowires form an increased surface area which enables the device itself to be kept as small as possible. Also having an increased surface area increases the sensitivity of the device and also allows for increase of the enzyme loading to functionalise the surface of the microneedles/nanowires. Furthermore the microneedles and nanowires are small and so this means that the sensor and associated biological fluid monitoring device can be made very small so making it less intrusive for a user. The microneedles and nanowires are covered by a membrane 207 which is porous to body fluids so the fluids can flow into the space around the microneedles/nanowires. The membrane may be porous to limit number of materials if further selection is required as to the material contacting the nanowires/microneedles.
The sensor formed of the microneedles/nanowires (which are coated with a conductive layer and then are functionalized) together with the membrane forms a first part, a) i.e. the sensor device part of a biological fluid monitoring device. The second part is the control part b) of the biological fluid monitoring device and this second part can be attached to the sensor and the second part provides the controls for the sensor. The controllers include a receiver e.g. a data recorder 204 and also a transmitter 205 which receives and forwards data from the sensor to a monitoring station and which controls and monitors the sensor periodically, transmitting information such as glucose levels and/or warnings to an external mobile device.
Furthermore, there is a built-in accelerometer 206 in the sensor electronics for the detection of movement/consciousness and fall of the user. The control part a) can be attached either permanently or releasable to the sensor part b). The whole device is then covered with an adhesive patch 208 to keep the device tight to the skin and watertight. Having parts a) and b) releasably connected to one another means that the sensor part can be discarded after a period of use and then a new sensor can be attached to the control part a). The control part can be reused by the user and data can then be collected for the life of the control part which is longer than that for the sensor part a).
The microneedles 1 typically will be 700 to 1000 μm meaning the device will be entirely painless as the microneedles are sized to avoid or minimize contact with nerve endings in the biological tissue, such as the dermis, thereby eliminating or reducing pain when the microneedles are inserted, for example into the skin. The microneedles are attached to a substrate 209 which forms the base of the microneedle(s) and this attaches the microneedle to a chip which is the interfaces with the control part a). There is no need for as bore in the microneedles as they are “bathed” in interstitial fluid.
Having the nanowires in alignment means that there is the maximum surface area available for the sensor, making it more sensitive and they are particularly useful in continuous glucose monitoring (CGM) sensors. The sensor can communicate via transmitters with external monitoring devices or may include an electronics package. The electronics package typically includes a power source (e.g., a battery), as well as electronic hardware and software for the transduction, storage, transmission, and display of measured values. The electronics package can be selectively fixed to the microneedle device, for example, so that the electronics package can be reused with a new, disposable microneedle device. The electronics package can include a mechanism for wireless or wire-based transmission of measured values to a remote device for analysis and/or display. The electronics also may include mathematical manipulation of the sensed data, for example, to average measured values or eliminate outlying datapoints so as to provide more useful measurements. This manipulation could also include prediction of trends over time. The electronics package also can include software and hardware to initiate or automate the sensing and analysis processes.
Calibration of the sensor can be accomplished using the concentration of a second analyte or the same analyte measured by another means. The primary analyte can be normalized, lowering extraction to extraction and site to site variability, by the concentration of the second analyte or same analyte from a separate measurement. Normalization may be a linear or non-linear relationship.
In a preferred embodiment for glucose sensing, a reusable sensor, which assays glucose concentration in interstitial fluid, can be calibrated daily by correlating interstitial fluid glucose values with values obtained from glucose measurements obtained from blood.
The microneedles and nanostructures which form the sensor all form one part of the device which is disposable. This part of the device can be releasably secured to the electronics of the sensor and a transmitter which can be used on a repeated basis with microneedles that have been replaced. The device will be attached to the individual by way of an adhesive patch or plaster when the microneedles, reservoir and sensor have been secured to the sensor electronics and transmitter.
The devices disclosed herein form minimally invasive bioassay devices and are also useful in the transport of biological fluids from within or across a variety of biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue; blood vessels; lymphatic vessels; cell membranes; epithelial tissue; and endothelial tissue. The biological barriers can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos. In preferred embodiments, biological fluids are withdrawn from skin, more preferably human skin, for minimally invasive diagnostic sensing. Biological fluids useful with the devices described herein include blood, lymph, interstitial fluid, and intracellular fluid. In a preferred embodiment, the biological fluid to be withdrawn or sensed is interstitial fluid.
A variety of analytes are routinely measured in the blood, lymph or other body fluids. Examples of typical analytes that can be measured include blood sugar (glucose), cholesterol, bilirubin, creatine, various metabolic enzymes, hemoglobin, heparin, hematocrit, vitamin K or other clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, and various reproductive hormones such as those associated with ovulation or pregnancy. Other substances or properties that would be desirable to detect include lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement). With the use of an appropriate receptor at the surface of the nanostructures, the technology can be applied to monitor other chronic diseases, such as heart diseases, stroke, chronic obstructive pulmonary diseases and asthma etc.
It is to be understood that the above embodiments have been provided only by way of exemplification of this invention, such as those detailed below, and that further modifications and improvements thereto, as would be apparent to persons skilled in the relevant art, are deemed to fall within the broad scope and ambit of the present invention described. Furthermore where individual embodiments are discussed, the invention is intended to cover combinations of those embodiments as well.
Number | Date | Country | Kind |
---|---|---|---|
1312669.3 | Jul 2013 | GB | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/GB2014/000287 | 6/14/2014 | WO | 00 |